Volume dodolan mangsa ngarep perusahaan Aura Biosciences (AURA)

Aura Biosciences Inc - logo grafis emiten AURA

Aura Biosciences, Inc. (AURA) develops targeted drugs for ocular oncology therapy, ensuring high margins while adhering to chemical disposal standards. Projected sales revenues confirm the financial potential, where 0.00 serves as the final level mark. However, fierce patent battles and advancements in genetic engineering create significant risks for the company's market positions.

Pendapatan mangsa ngarep perusahaan: Aura Corp (AURA) kanggo 04.07.2022 - 19.11.2026

Rincian metrik keuangan lan pasar Aura Bio (AURA)

- rincian kapitalisasi pasar:
Analisis umum perusahaan:Aura Biosciences Inc
Sampel barang Aura Biosciences Inc

Expected sales volume reflects a temporary business discount relative to its fundamental potential, capturing periods of asset accumulation before the valuation gap is closed. The current calculated level of 0.00 at the target product realization level measures the market undervaluation of future cash flows, which are expected to be generated by the innovations of leading ophthalmic oncologists and their advanced laboratory infrastructure for Aura Biosciences, Inc. (AURA).

Pesaing utama

Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan pendapatan perusahaan ymabs.com (YMAB)|Prakiraan pendapatan perusahaan CADL (Candel)|Accuray, Inc. - Volume dodolan mangsa ngarep perusahaan|SELLAS Life Sciences Group Inc. - Prakiraan pendapatan perusahaan|ACTU: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan Citius Oncology Inc|HURA: Prakiraan volume dodolan|TARA: Prakiraan volume pendapatan perusahaan|FATE (fatetherapeutics.com) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Aadi Bioscience Inc (WHWK)|Prakiraan volume dodolan TCRX|CSBR - Volume dodolan sing dikarepake perusahaan|Prakiraan volume dodolan XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Volume dodolan sing dikarepake perusahaan|OSTX: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RADX (Radiopharm Theranostics)|Artiva (ARTV) - Prakiraan pendapatan perusahaan|ANL: Prakiraan volume pendapatan perusahaan|VERU (Veru Corporation) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Tempest Therapeutics, Inc. TPST|Prakiraan volume dodolan XLO|Renovaro - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Mural Bio MURA|KAPA: Prakiraan pendapatan perusahaan|OnKure Therapeutics - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan w2.cytomed.sg GDTC|CRIS: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Apollomics Inc.|THAR (Tharimmune Corporation) - Prakiraan volume dodolan|Prakiraan volume dodolan Advanced Biomed Inc|Prakiraan volume dodolan GNPX|Volume dodolan mangsa ngarep perusahaan Calidi Biotherapeutics Inc. CLDI|Prakiraan pendapatan perusahaan Sunshine Biopharma Inc. SBFM|Dodolan mangsa ngarep perusahaan Xenetic Biosciences (XBIO)|SLRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Kitov Pharma|AON (AONC) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan